---
author: Harvey Guo
created: 2024-10-15 15:57
modified: 2024-10-15 15:57
aliases:
  - Antiplatelets
  - Antiplatelet
share: true
---
![[Pasted image 20241015162951.png|Pasted image 20241015162951.png]]
# Irreversible cyclooxygenase inhibitors
---
## Agents 
Acetylsalicylic acid (ASA, aspirin)
## Mechanism of action 
ASA covalently attaches an acetyl group to COX.![[Pasted image 20240317220254.png|Pasted image 20240317220254.png]]
- <span style="background:rgba(240, 200, 0, 0.2)">Irreversible COX-1 inhibition → inhibition of thromboxane (TXA2) synthesis in platelets → inhibition of platelet aggregation (antithrombotic effect)</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Onset of antiplatelet action: within minutes</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Duration of antiplatelet action: 7–10 days </span>
- <span style="background:rgba(240, 200, 0, 0.2)">Irreversible COX-1 and COX-2 inhibition → inhibition of prostacyclin and prostaglandin synthesis → antipyretic, anti-inflammatory, and analgesic effect </span>
	- COX-2 is more resistant to inhibition than COX-1. Therefore, higher doses of aspirin are required to achieve the antipyretic, anti-inflammatory, and analgesic effects.
## Effects
- Low dose (below 300 mg/day): inhibition of platelet aggregation
- Intermediate dose (300-2400 mg/day): antipyretic and analgesic effect
- High dose (2400-4000 mg/day): antiinflammatory effect
# P2Y12 receptor antagonists
---
## Agents 
- <span style="background:rgba(240, 200, 0, 0.2)">Clopidogrel</span>
	- Pro-drug
	- Activation is dependent on hepatic cytochrome P enzymes.
	- Not effective in individuals with genetic polymorphisms of CYP enzymes or drug-induced inhibition of CYP enzymes (e.g., cimetidine, amiodarone, omeprazole, etc.)
- Prasugrel
	- Pro-drug
	- Faster acting and more potent than clopidogrel
- <span style="background:rgba(240, 200, 0, 0.2)">Ticagrelor</span>
	- Not a pro-drug
	- Orally administered direct antagonist of P2Y12 platelet receptor
	- Faster acting and more potent than clopidogrel
- Ticlopidine: irreversible P2Y12 receptor antagonist
## Mechanism of action
- <span style="background:rgba(240, 200, 0, 0.2)">Inhibition of P2Y12 receptor on platelets (ADP receptor) → ↓ expression of Gp IIb/IIIa receptors on platelets → inhibition of platelet aggregation</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">ADP usually binds to P2Y12 receptors, leading to activation of Gp IIb/IIIa receptors and subsequent platelet aggregation.</span>
	- Irreversible inhibition: clopidogrel, prasugrel, ticlopidine
	- Reversible inhibition: ticagrelor
# Glycoprotein IIb/IIIa inhibitors
---
## Agents
- <span style="background:rgba(240, 200, 0, 0.2)">Abciximab (Fab region fragments of monoclonal antibodies against glycoprotein IIb/IIIa receptors)</span>
- <span style="background:rgba(240, 200, 0, 0.2)">Eptifibatide</span>
- <span style="background:rgba(240, 200, 0, 0.2)">Tirofiban</span> 
## Mechanism of action 
- <span style="background:rgba(240, 200, 0, 0.2)">Gp IIb/IIIa inhibitors bind to and block glycoprotein IIb/IIIa receptors (fibrinogen receptor) on the surface of activated platelets → prevention of platelets binding to fibrinogen  → inhibition of platelet aggregation and thrombus formation</span>
## Indication 
- <span style="background:rgba(240, 200, 0, 0.2)">Prevention of thrombotic complications</span> in high-risk patients with unstable angina/NSTEMI planned for PCI within 24 hours 

>[!Mnemonic] 
>- To remember that <font color="#ffc000">ABC</font>iximab targets glycoproteins <font color="#ffc000">IIb/IIIa</font>, think <font color="#ffc000">ABC</font> rhymes with <font color="#ffc000">123</font>!
>- Epti<font color="#ffc000">fib</font>atide and tiro<font color="#ffc000">fib</font>an are <font color="#ffc000">fibrinogen</font> receptor blockers.